The HyNOVA study has officially opened to recruitment after activating its first site, Peter MacCallum Cancer Centre and Royal Women’s Hospital.
Researchers of the HyNOVA study are seeking 80 participants at five sites across Australia, with Chris O’Brien Lifehouse/Royal Prince Alfred Hospital and Mater Hospital to be activated next.
HyNOVA is a randomised study comparing hyperthermic and normothermic intraperitoneal chemotherapy, following interval cytoreductive surgery for stage III epithelial ovarian, fallopian tube and primary peritoneal cancer. HyNOVA aims to determine the efficacy of heat during ovarian cancer surgery and chemotherapy.
The ANZGOG study is in collaboration with the NHMRC Clinical Trials Centre, at the University of Sydney, and funded by the Medical Research Future Fund.
Watch Principal Investigator, Assoc Prof Rhonda Farrell, explain the HyNOVA study:
Want to know more about ANZGOG’s clinical trials?
To find out more about ANZGOG’s clinical trials, click here.
